Some low-solubility compounds improve with micronization; others do not dissolve adequately regardless of particle size. When salt selection, cocrystal development, micronization, or crystalline-form selection cannot solve exposure risk, amorphous materials or amorphous solid dispersions may be appropriate.
A non-crystalline material produces an essentially continuous XRPD pattern often called an X-ray amorphous pattern. That pattern can still contain information about local molecular order, short-range packing, and structural change.
Triclinic applies total diffraction analysis, molecular modeling, thermal methods, spectroscopy, microscopy, and stress studies to understand whether a non-crystalline material is stable enough to carry through development and shelf life.
That distinction matters because amorphous materials with similar bulk XRPD appearance may differ in local order, water response, and crystallization tendency. A useful amorphous study therefore compares how the amorphous halo, thermal behavior, spectroscopic signal, and stability response change with production route and stress condition.
Triclinic guides amorphous material development by evaluating stability of materials produced by different routes, comparing formulations, and developing assays to determine whether material remains amorphous or contains crystalline components.
Spray drying rapidly evaporates solvent from solution microdroplets, reducing the opportunity for API molecules to reorient and crystallize compared with bulk evaporation. Small-scale spray drying can be evaluated as part of polymorph or amorphous screening when the API has suitable thermal and solvent properties.
| ASD question | Development implication | Triclinic evaluation |
|---|---|---|
| Is the API a fast or slow crystallizer? | Fast crystallizers may require stronger polymer selection or different processing. | Amorphous generation, stress, and recrystallization testing. |
| What is the solubility advantage? | ASD only helps if the amorphous state provides a useful performance gain. | Dissolution and supersaturation comparison against crystalline material. |
| Which polymer and loading are appropriate? | Polymer choice and drug loading control stability, manufacturability, and performance. | Polymer toolbox screen, loading assessment, and stability ranking. |
| What storage conditions are needed? | Temperature and humidity can drive physical aging or recrystallization. | Tg, DVS, controlled RH/temperature stress, and phase-specific analysis. |
Dissolution testing should be paired with residual-solid analysis. Apparent performance can look acceptable while crystallization is occurring in a subset of particles or after polymer dissolution, especially when phase separation is present.
An amorphous strategy should start with the performance problem and the failure mode, not with the assumption that every poorly soluble compound belongs in an ASD. Triclinic first separates solubility limitation, dissolution-rate limitation, crystallization tendency, moisture sensitivity, and formulation matrix effects so the study is aimed at the decision the program actually has to make.
The practical output is a control recommendation: whether an amorphous route is justified, which processing and polymer variables deserve testing, which residual-solid analyses are required after dissolution, and which method can detect recrystallization or unintended crystalline content at the relevant development stage.
Amorphous content can raise apparent solubility and dissolution, but it also increases recrystallization and moisture-sensitivity risk. A strong amorphous-material program separates short-term performance from a physical state that can be maintained through processing, storage, and use.
Residual-solid analysis matters because attractive dissolution or PK may reflect a temporary amorphous, mixed, hydrated, or solvated state rather than a developable material strategy.
| Decision signal | What to test | Actionable output |
|---|---|---|
| Apparent solubility gain | The non-crystalline state may temporarily increase supersaturation. | Pair dissolution with residual-solid and stability analysis. |
| Moisture sensitivity | Water can plasticize amorphous material and accelerate recrystallization. | Use DVS, DSC/Tg, PXRD, Raman/ssNMR, and controlled humidity stress. |
| ASD feasibility | Polymer choice and drug loading determine whether performance can be maintained. | Rank formulation candidates by stability, dissolution, and phase-specific characterization. |
Application-note examples include mDSC-based quantitation of amorphous content in crystalline API, rapid ASD development using nifedipine, and evaluation of acetaminophen spray-dried dispersions by low-frequency Raman mapping.
These examples highlight the same practical requirement: do not rely on performance data alone. Link dissolution, solubility, Tg, water uptake, and stability behavior to phase-specific solid-state analysis.
Determine whether an API can exist in multiple crystalline forms and whether form differences change solubility, dissolution, stability, manufacturing, drug-product performance, or IP.
View serviceScreen ionizable APIs for counterions that improve crystallinity, solubility, dissolution, stability, manufacturability, or developability while controlling disproportionation risk.
View serviceUse coformer selection, phase-diagram logic, crystallization methods, and formulation strategy to improve properties and expand solid-form options.
View serviceBuild reproducible crystallization processes that control the chosen solid form, particle attributes, purity, and scale-up behavior.
View serviceResolve form conversion, failed crystallizations, process sensitivity, stability drift, unexplained PK/dissolution changes, and batch-to-batch material differences.
View serviceAn amorphous pharmaceutical solid is a noncrystalline material that lacks the long-range periodic molecular order found in a crystal. Its molecules are immobilized in a disordered arrangement resembling a structurally arrested liquid. Because the amorphous state usually has higher free energy and molecular mobility than the corresponding crystal, it may provide greater apparent solubility and faster dissolution but is generally more susceptible to physical aging, moisture effects, and recrystallization.
An amorphous form is advantageous when the crystalline API has inadequate solubility or dissolution and the increased free energy of the amorphous state can produce a clinically meaningful performance benefit. It may also be useful when crystallization is difficult, when a formulation must maintain supersaturation, or when an amorphous matrix improves processing. The benefit is worthwhile only if physical and chemical stability, manufacturability, drug loading, and product performance can be controlled throughout the intended shelf life.
Amorphous materials are metastable because they possess greater free energy than the thermodynamically stable crystalline state. Their disordered molecular arrangement is kinetically trapped rather than at equilibrium. Over time, molecular mobility permits structural relaxation, phase separation, nucleation, and crystal growth. The rate of transformation depends on temperature, moisture, glass transition, molecular structure, impurities, residual crystallinity, formulation composition, and processing history.
Glass-transition temperature, or Tg, is used as an indicator of molecular mobility, physical stability, processing behavior, and storage risk in amorphous pharmaceutical materials. Below Tg, molecular mobility is comparatively restricted; as temperature approaches or exceeds Tg, mobility increases and crystallization, phase separation, structural relaxation, softening, and chemical degradation may accelerate. Tg is an important development parameter, but it is not an absolute stability threshold and should be interpreted together with moisture content, formulation composition, molecular interactions, thermal history, and direct stability data.
Recrystallization risk is evaluated by combining structural, thermal, moisture-sorption, mobility, and stability studies under conditions relevant to manufacture, storage, and use. Important factors include glass-transition temperature, molecular mobility, water and residual-solvent plasticization, residual crystal seeds, API–polymer miscibility, drug loading, phase separation, processing stress, and crystallization kinetics. No single accelerated test can establish long-term stability; risk should be assessed through orthogonal methods and mechanistically relevant challenge conditions.
Moisture is one of the most important determinants of amorphous-material stability. Water commonly acts as a plasticizer, lowering glass-transition temperature, increasing molecular mobility, and accelerating physical aging, phase separation, recrystallization, agglomeration, and some chemical-degradation pathways. Moisture may also alter API–polymer interactions, create hydrates, change dissolution performance, or cause irreversible structural transformation. Stability must therefore be evaluated as a function of water activity, moisture content, exposure time, temperature, formulation composition, and packaging.
Amorphous solid dispersions are characterized using orthogonal techniques that evaluate crystallinity, glass transition, phase homogeneity, API–polymer interactions, composition, moisture response, chemical stability, particle properties, and dissolution performance. XRPD and modulated DSC are foundational, but they cannot independently establish molecular-level miscibility, absence of low-level crystallinity, or long-term stability. A meaningful characterization strategy links physical state and composition to manufacturing history, storage behavior, and product performance.
Common failure mechanisms include recrystallization, moisture plasticization, amorphous–amorphous phase separation, physical aging, chemical degradation, inadequate drug–polymer miscibility, residual crystallinity, excessive drug loading, process-induced transformation, poor supersaturation maintenance, and inadequate packaging. Programs also fail when absence of XRPD peaks is treated as proof of stability or when a formulation is optimized for dissolution without considering manufacturability and shelf life.
Send the material history, current data package, process conditions, development objective, and timeline. Triclinic will route the request to the right solid-form scientist.
